title: Bone mineral density in statin users: a population-based analysis from a Spanish cohort.
abstract: We studied 2,315 subjects (1,422 women and 893 men) from the Camargo Cohort and analyzed the differences in BMD between statin or non-statin users. We also studied effects of the type of statin, dose, pharmacokinetic properties, and length of treatment on bone mineral density (BMD). Of the subjects, 478 (21 %) were taking statins (256 women and 222 men). Overall, they had higher BMD than non-users (p < 0.0001). In adjusted multivariate models, women taking statins had higher BMD at femoral neck (p = 0.002) and total hip (p = 0.04) than non- users. No differences were found in men. Women taking simvastatin had higher increases in BMD than non-statin users at femoral neck (p = 0.02) and total hip (p = 0.009), those taking fluvastatin had lower BMD values at lumbar spine (p = 0.028), and those receiving lovastatin had higher increases at femoral neck (p = 0.006). In men, only atorvastatin was associated with higher femoral neck BMD than non-statin use (p = 0.029). Comparing with non-statin users, only women receiving lipophilic statins had greater BMD at femoral neck (p = 0.003). According to drug potency, women on high- or lower-potency agents showed higher BMD values at femoral neck than non-users (p = 0.028 and 0.022, respectively). In men, only high-potency statins were associated with higher femoral neck BMD than non-use (p = 0.021). No differences between dose or length of statin therapy were noted regarding BMD in either sex. In summary, in a large population-based cohort, women on statins had higher BMD at the hip than non-users. Overall, this increase in BMD was more evident in subjects on lipophilic or high-potency statins.
authors.affiliation: Bone Metabolic Unit, Department of Internal Medicine, Hospital Universitario Marqués de Valdecilla, University of Cantabria, IFIMAV, Red temática de investigación cooperativa en envejecimiento y fragilidad (RETICEF), Cantabria, Spain, hernandezjluis@gmail.com.
authors.forename: José L
authors.initials: JL
authors.lastname: Hernández
authors.forename: José M
authors.initials: JM
authors.lastname: Olmos
authors.forename: Galo
authors.initials: G
authors.lastname: Romaña
authors.forename: Josefina
authors.initials: J
authors.lastname: Martinez
authors.forename: Jesús
authors.initials: J
authors.lastname: Castillo
authors.forename: Irina
authors.initials: I
authors.lastname: Yezerska
authors.forename: Gabriel
authors.initials: G
authors.lastname: Pinedo
authors.forename: Jesús
authors.initials: J
authors.lastname: González-Macías
mesh_terms: D000368:Aged; D015519:Bone Density / Q000187:drug effects*; D015331:Cohort Studies; D005260:Female; D006615:Hip / Q000033:anatomy & histology*; D006801:Humans; D000960:Hypolipidemic Agents / Q000493:pharmacokinetics / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D013030:Spain; D013997:Time Factors
chemical_list: D000960:Hypolipidemic Agents